With deep insight into tumor antigens and T cell activation, we develop curative treatments for patients with no available treatment today.

Neoantigens   Solid tumors       Poke-103

Neoantigens form a unique set of targets in many solid tumors, e.g., Bladder-, lung-, Head & Neck-, Uterine- and  Colon cancer, etc.

Poke-103 is a multitargetted T cell product responding against neoantigens identified for each individual patient with PokeAcells proprietary neoantigen AIM. The Poke-103 T cell product is created with PokeAcell’s ImmPACT activation technology for optimal phenotype and process simplicity. Following pre-clinical testing, PokeAcell will pursue clinical testing in a basket trial covering multiple types of solid tumors.

Merkel Cell Carcinoma   Poke-102

Merkel Cell Carcinoma is an aggressive virus-induced rare form of skin cancer. Merkel Cell Carcinoma patients who do not respond to checkpoint inhibitors lack a sufficient T cell response and have no other treatment options today. PokeAcell aim to provide the T cell product needed to help them.

Poke-102 is a virus antigen responding T cell product created from the PokeAcell ImmPACT activation technology with selected Merkel Cell Carcinoma virus antigens.

Feasibility trial         Poke-101


PokeAcell is conducting a feasibility trial in collaboration with National Center for Cancer Immune Therapy at Herlev Hospital focused on Metastatic Melanoma.

Poke-101 is a multitargetted T cell product responding against Melanoma shared antigens. Poke-101 is created with PokeAcell’s ImmPACT activation technology and 30 carefully selected Melanoma antigens. The trial in focused on Metastatic Melanoma, which the type of cancer that best responds to immunotherapy and known to respond to T cell therapy with Tumor Infiltrating Lymphocytes. The objective of the trial is to test manufacturing feasibility and treatment safety.



Next generation antigens and ImmPACT applications

The precision activation of the ImmPACT platform offer many opportunities in cell therapy. Multiple cancers can be addressed with detailed insight into the antigen landscape. The ImmPACT activation can also be applied with new approached in cell therapy and PokeAcell are working to extend the benefit for patients with great unmet needs.